Forticell Bioscience, Incorporation - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Forticell Bioscience, Incorporation Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Forticell Bioscience, Incorporation Formerly known as Ortec International, Inc.. The Group's principal activity is to conduct research and development of tissue engineered skin regeneration product, for use in the treatment of chronic and acute wounds. The Group has developed a proprietary and patented technology known as OrCel, which is used to stimulate the repair and regeneration of human skin. OrCel is a two layered tissue engineered dressing that consists of human derived skin cells, both dermal and epidermal, supported within a porous collagen matrix. The composite matrix is seeded with keratinocytes for epidermal growth and fibroblasts for dermal growth. The Group also conducts a pivotal clinical trial for the use of OrCel in its cryopreserved form for the treatment of venous leg stasis and diabetic foot ulcers. The Group operates predominantly in the domestic market.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report